← ANALYST RATINGS · TIPRANKS
Vicore Pharma Holding AB Sponsored ADR (VCRE): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $25.00, the highest $25.00, the lowest $25.00. The average is +178.4% from the last price of $8.98.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $25.00 | Buy | +178.4% | Initiated | 09.10.26on TipRanks Oct 12 02:07 | +1.4%next day +2.6% · 5 days +1.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 12.10.26: target $25.00 at a price of $9.00 (+177.8%); now: $25.00 at $8.98 (+178.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.53 (from $-0.55 to $-0.51). Last quarter: $-0.54.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · General
About Vicore Pharma Holding AB Sponsored ADR
- CEO: Ahmed Mousa
- Employees: 37
- Kornhamnstorg 53, Stockholm, AB, 111 27, SE
- vicorepharma.com
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Data from the stock’s TipRanks forecast page, read 318 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗